Exicure, Inc. (Nasdaq: XCUR) released its financial results for the second quarter of 2025, reporting a net loss of $2.6 million, an increase from the $0.6 million net loss reported in the same quarter of 2024. This $2 million increase in net loss was primarily attributed to the heightened operating expenses following the acquisition of GPCR Therapeutics USA Inc. ("GPCR USA"). The company's cash and cash equivalents stood at $7.9 million as of June 30, 2025, down from $12.5 million at the end of 2024. Research and development expenses for the quarter were $0.9 million, compared to $0 in the corresponding quarter of the previous year, due to costs associated with GPCR USA's research efforts. General and administrative expenses rose to $1.5 million from $1.2 million, reflecting additional costs related to the acquisition and increased professional services. Exicure also reported a $60,000 loss from the sale of GPCR USA's fixed assets and a $159,000 loss from changes in the fair value of its contingent liability. The company indicated that its current cash position is insufficient to sustain operations without obtaining substantial additional financing in the short term.